Loading
A phase 1/2 trial of T3011, Pembrolizumab in melanoma, run by ImmVira Pharma Co. Ltd, now recruiting.
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04370587 by ImmVira Pharma Co. Ltd, with 30 participants planned, started 2020-09-17 and due to reach its primary completion in 2026-09-22. Interventions recorded: T3011, T3011 + pembrolizumab. Conditions listed: Solid Tumor, Melanoma, HNSCC, Sarcoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/